Stock Yards Bank & Trust Co. lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 14.0% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,980 shares of the medical equipment provider’s stock after selling 485 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Zimmer Biomet were worth $323,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Chicago Partners Investment Group LLC raised its stake in shares of Zimmer Biomet by 3.3% in the 4th quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock valued at $349,000 after acquiring an additional 92 shares during the period. North Star Investment Management Corp. lifted its stake in shares of Zimmer Biomet by 16.6% during the first quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock worth $88,000 after purchasing an additional 95 shares in the last quarter. First Bancorp Inc ME boosted its position in shares of Zimmer Biomet by 5.3% in the first quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock worth $260,000 after buying an additional 100 shares during the period. Ballentine Partners LLC grew its stake in shares of Zimmer Biomet by 2.6% in the first quarter. Ballentine Partners LLC now owns 3,957 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 100 shares in the last quarter. Finally, Romano Brothers AND Company raised its holdings in shares of Zimmer Biomet by 1.1% during the 1st quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock valued at $1,256,000 after buying an additional 100 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.
Zimmer Biomet Stock Up 0.1 %
Shares of NYSE:ZBH opened at $106.34 on Thursday. The company’s fifty day moving average is $109.92 and its two-hundred day moving average is $115.72. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $133.90. The stock has a market capitalization of $21.66 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02.
Zimmer Biomet Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. Zimmer Biomet’s payout ratio is currently 20.78%.
Analysts Set New Price Targets
Several brokerages have issued reports on ZBH. Robert W. Baird lowered their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Raymond James lowered their price target on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. JPMorgan Chase & Co. cut their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday. Canaccord Genuity Group lowered their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 10th. Finally, Oppenheimer cut their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $125.17.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Featured Articles
- Five stocks we like better than Zimmer Biomet
- What is the S&P/TSX Index?
- How Much Can You Make in Stocks in One Month?
- The 3 Best Blue-Chip Stocks to Buy Now
- This Is the Top Large-Cap Stock Insiders Are Buying
- Options Trading – Understanding Strike Price
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.